港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

映恩生物-B

200.200

+4.7002.40%

成交量：103.73万

成交额：2.10亿

市值：181.83亿

市盈率：-5.03

高：207.800

开：202.000

低：198.300

收：195.500

52周最高：563.500

52周最低：158.500

股本：9,082.42万

香港流通股本：9,082.42万

量比：1.39

换手率：1.14%

股息：- -

股息率：- -

每股收益(LYR):-39.800

净资产收益率：-1282.14%

总资产收益率：-9.61%

市净率：6.43

市盈率(LYR):-5.03

市销率: 8.43

数据加载中...

总览公司新闻公告

异动解读｜映恩生物-B盘中上涨5.56%，瑞银首次覆盖给予买入评级叠加板块走强

瑞银：映恩生物-B首次覆盖给予“买入”评级目标价320港元

异动解读｜映恩生物-B盘中下跌5.14%，报182.7港元

瑞银：首次复盖映恩生物-B(09606.HK)予“买入”评级目标价320港元

《大行》瑞银首次覆盖映恩生物(09606.HK)予“买入”评级目标价320元

阿斯达克财经

映恩生物-B(09606)拟于2026年8月28日审议中期业绩

【券商聚焦】招商证券首予映恩生物（09606）强烈推荐评级指ADC管线差异化优势显著

异动解读｜映恩生物-B盘中上涨5.28%，生物科技板块集体走强延续估值修复

异动解读｜映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续

映恩生物-B更新2026年7月股份变动月报表，总股本增至91,224,314股

异动解读｜映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振

异动解读｜映恩生物-B盘中下跌5.23%，GSK竞争压力与减持忧虑延续

一周港股牛熊榜 | 海致科技周涨40%问鼎牛榜榜首；清盘人重启股权出售计划，恒大物业周涨23%；伟禄科技暴跌33%，遭大股东减持12%

老虎资讯综合

映恩生物－Ｂ(09606)股价下跌5.038%，现价港币$222.4

阿斯达克财经

【券商聚焦】中国银河证券首予映恩生物(09606)推荐评级指其ADC管线梯队完善

异动解读｜映恩生物-B盘中下跌5.15%，报228.4港元

智通港股解盘 | 魔咒解除各种刺激再起 Token概念股走势凶猛

港股异动 | 映恩生物-B(09606.HK)午后涨近15% B7-H3 ADC拟纳入突破性疗法

异动解读｜映恩生物-B盘中上涨7.07%，DB-1310临床数据披露叠加合作方Avenzo完成纳斯达克上市

异动解读｜映恩生物-B盘中下跌5.99%，报220.8港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/09606/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":200.2,"timestamp":1787904513012,"preClose":195.5,"halted":0,"volume":1037341,"delay":0,"changeRate":0.024040920716112475,"floatShares":90824200,"shares":90824200,"eps":-39.8,"marketStatus":"休市中","change":4.7,"latestTime":"08-28 16:08:33","open":202,"high":207.8,"low":198.3,"amount":210074416,"amplitude":0.048593,"askPrice":200.2,"askSize":700,"bidPrice":200,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-31.631,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":7,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":195.5,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"volumeRatio":1.3893634652878806,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":90824200,"roa":"-9.61%","roe":"-1282.14%","lyrEps":-39.8,"volumeRatio":1.3893634652878806,"shares":90824200,"dividePrice":0,"high":207.8,"amplitude":0.048593,"preClose":195.5,"low":198.3,"week52Low":158.5,"pbRate":"6.43","psRate":"8.43","week52High":563.5,"institutionHeld":0,"latestPrice":200.2,"committee":-0.272727,"eps":-39.8,"divideRate":0,"volume":1037341,"delay":0,"ttmEps":-31.631,"open":202,"prevYearClose":298.2,"prevWeekClose":194.5,"prevMonthClose":181.8,"prevQuarterClose":181.2,"fiveDayClose":194.5,"twentyDayClose":181.8,"sixtyDayClose":200.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-23","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-26","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2026-08-28","current":-6.329234,"percent":0.884273,"low":-29.984477,"twenty":-16.253166,"median":-9.270261,"eighty":-6.767757,"high":-4.703556,"avg":-11.594196,"sd":6.228829,"marketCap":18108653362},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638},{"date":"2025-05-09","current":-15.074661,"twenty":-16.551291,"median":-15.826729,"eighty":-15.074661,"marketCap":17010399982},{"date":"2025-05-16","current":-15.043786,"twenty":-16.438538,"median":-15.220044,"eighty":-14.405796,"marketCap":17114249721},{"date":"2025-05-23","current":-16.495727,"twenty":-16.438538,"median":-15.262587,"eighty":-14.582474,"marketCap":18822153243},{"date":"2025-05-30","current":-16.208434,"twenty":-16.401371,"median":-15.460562,"eighty":-14.726132,"marketCap":18575651704},{"date":"2025-06-06","current":-16.427701,"twenty":-16.438538,"median":-15.666395,"eighty":-14.905978,"marketCap":18874975001},{"date":"2025-06-13","current":-20.940103,"twenty":-16.693343,"median":-15.893657,"eighty":-15.005253,"marketCap":24069114577},{"date":"2025-06-20","current":-18.479443,"twenty":-18.428819,"median":-16.104695,"eighty":-15.043786,"marketCap":21199132371},{"date":"2025-06-27","current":-18.0452,"twenty":-18.863356,"median":-16.282988,"eighty":-15.074661,"marketCap":20758951051},{"date":"2025-07-04","current":-21.227749,"twenty":-18.942282,"median":-16.427701,"eighty":-15.074735,"marketCap":24421259633},{"date":"2025-07-11","current":-22.045806,"twenty":-19.683704,"median":-16.508309,"eighty":-15.190609,"marketCap":25336836779},{"date":"2025-07-18","current":-25.758166,"twenty":-20.839221,"median":-16.693343,"eighty":-15.21995,"marketCap":29580184704},{"date":"2025-07-25","current":-25.970367,"twenty":-21.539184,"median":-16.981252,"eighty":-15.260218,"marketCap":29932329760},{"date":"2025-08-01","current":-24.963588,"twenty":-22.267132,"median":-18.096065,"eighty":-15.298157,"marketCap":28594178547},{"date":"2025-08-08","current":-27.998627,"twenty":-24.402884,"median":-18.454131,"eighty":-15.429476,"marketCap":32150843612},{"date":"2025-08-15","current":-27.487815,"twenty":-25.397092,"median":-18.863356,"eighty":-15.513126,"marketCap":31516982512},{"date":"2025-08-22","current":-26.341915,"twenty":-25.761111,"median":-19.052333,"eighty":-15.750472,"marketCap":30108402288},{"date":"2025-08-29","current":-8.977182,"twenty":-25.761111,"median":-19.118727,"eighty":-15.513126,"marketCap":27784244918},{"date":"2025-09-05","current":-10.341403,"twenty":-25.547361,"median":-18.897362,"eighty":-15.21995,"marketCap":31974771084},{"date":"2025-09-12","current":-12.806892,"twenty":-25.484142,"median":-18.479443,"eighty":-15.036079,"marketCap":39669140558},{"date":"2025-09-19","current":-11.291493,"twenty":-25.397092,"median":-18.151913,"eighty":-14.569138,"marketCap":34950396808},{"date":"2025-09-26","current":-9.575685,"twenty":-25.265241,"median":-17.183112,"eighty":-14.242848,"marketCap":29562577451},{"date":"2025-10-03","current":-9.769092,"twenty":-25.225948,"median":-16.756996,"eighty":-13.467837,"marketCap":30231653057},{"date":"2025-10-10","current":-8.39875,"twenty":-25.201143,"median":-16.551291,"eighty":-12.508489,"marketCap":25953090627},{"date":"2025-10-17","current":-9.52866,"twenty":-25.090759,"median":-16.467132,"eighty":-11.127698,"marketCap":29421719428},{"date":"2025-10-24","current":-8.24833,"twenty":-24.683236,"median":-16.401371,"eighty":-10.383008,"marketCap":25477694801},{"date":"2025-10-31","current":-8.936138,"twenty":-24.228898,"median":-16.208434,"eighty":-10.01166,"marketCap":27643386896},{"date":"2025-11-07","current":-8.115895,"twenty":-24.0933,"median":-15.983588,"eighty":-9.661913,"marketCap":25090335240},{"date":"2025-11-14","current":-9.615008,"twenty":-24.036348,"median":-15.846935,"eighty":-9.533336,"marketCap":29809078990},{"date":"2025-11-21","current":-8.88084,"twenty":-23.659864,"median":-15.493415,"eighty":-9.411746,"marketCap":27520136126},{"date":"2025-11-28","current":-9.805814,"twenty":-23.032171,"median":-15.270261,"eighty":-9.358381,"marketCap":30496838785},{"date":"2025-12-05","current":-9.522579,"twenty":-22.810207,"median":-15.147164,"eighty":-9.358381,"marketCap":29666872704},{"date":"2025-12-12","current":-9.227769,"twenty":-22.078047,"median":-15.043786,"eighty":-9.232281,"marketCap":28801588916},{"date":"2025-12-19","current":-9.562517,"twenty":-22.024358,"median":-14.816055,"eighty":-9.195431,"marketCap":29916743432},{"date":"2025-12-24","current":-8.86445,"twenty":-21.960012,"median":-14.582474,"eighty":-9.185632,"marketCap":27819193982},{"date":"2026-01-02","current":-8.361415,"twenty":-21.780535,"median":-14.405796,"eighty":-9.071858,"marketCap":26343799029},{"date":"2026-01-09","current":-10.158481,"twenty":-21.573184,"median":-14.143758,"eighty":-9.138635,"marketCap":32085396254},{"date":"2026-01-16","current":-10.130227,"twenty":-21.338723,"median":-13.671075,"eighty":-9.159542,"marketCap":32100133626},{"date":"2026-01-23","current":-9.450777,"twenty":-21.128733,"median":-12.833558,"eighty":-9.159542,"marketCap":29918397524},{"date":"2026-01-30","current":-9.27281,"twenty":-20.989151,"median":-11.556174,"eighty":-9.159542,"marketCap":29489203537},{"date":"2026-02-06","current":-8.834279,"twenty":-20.864442,"median":-11.154997,"eighty":-9.026205,"marketCap":28165855410},{"date":"2026-02-13","current":-9.445101,"twenty":-20.730279,"median":-10.443288,"eighty":-9.076015,"marketCap":30286271904},{"date":"2026-02-20","current":-9.824687,"twenty":-20.674464,"median":-10.43817,"eighty":-9.09489,"marketCap":31458062186},{"date":"2026-02-27","current":-8.771359,"twenty":-20.006759,"median":-10.305855,"eighty":-9.047703,"marketCap":28393379910},{"date":"2026-03-06","current":-8.859488,"twenty":-19.896232,"median":-10.18539,"eighty":-8.969972,"marketCap":28447462538},{"date":"2026-03-13","current":-7.555838,"twenty":-19.630572,"median":-10.144354,"eighty":-8.935093,"marketCap":24373237865},{"date":"2026-03-20","current":-7.859442,"twenty":-19.432697,"median":-9.991099,"eighty":-8.867218,"marketCap":25256587462},{"date":"2026-03-27","current":-8.718949,"twenty":-19.118727,"median":-9.951719,"eighty":-8.854358,"marketCap":25617138318},{"date":"2026-04-02","current":-9.880216,"twenty":-19.012497,"median":-9.885599,"eighty":-8.850342,"marketCap":29168564250},{"date":"2026-04-10","current":-9.180446,"twenty":-18.964111,"median":-9.878849,"eighty":-8.85641,"marketCap":27311727342},{"date":"2026-04-17","current":-9.417233,"twenty":-18.904163,"median":-9.820225,"eighty":-8.842311,"marketCap":28027927148},{"date":"2026-04-24","current":-8.878352,"twenty":-18.860571,"median":-9.805814,"eighty":-8.846908,"marketCap":26425587896},{"date":"2026-04-30","current":-8.372511,"twenty":-18.781003,"median":-9.783435,"eighty":-8.82699,"marketCap":24926391864},{"date":"2026-05-08","current":-7.738947,"twenty":-18.469318,"median":-9.736996,"eighty":-8.785939,"marketCap":23120131584},{"date":"2026-05-15","current":-6.609967,"twenty":-18.384608,"median":-9.691452,"eighty":-8.751075,"marketCap":20699742808},{"date":"2026-05-22","current":-6.440114,"twenty":-18.185423,"median":-9.652725,"eighty":-8.708072,"marketCap":20121739519},{"date":"2026-05-29","current":-6.506712,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"marketCap":20400514838},{"date":"2026-06-05","current":-5.374082,"twenty":-18.0452,"median":-9.575685,"eighty":-8.511806,"marketCap":16873830092},{"date":"2026-06-12","current":-5.36331,"twenty":-17.183112,"median":-9.557279,"eighty":-8.481744,"marketCap":16828616185},{"date":"2026-06-18","current":-5.321722,"twenty":-16.860136,"median":-9.537613,"eighty":-8.412993,"marketCap":16738188371},{"date":"2026-06-26","current":-4.703556,"twenty":-16.761475,"median":-9.522579,"eighty":-8.375473,"marketCap":14721648119},{"date":"2026-07-03","current":-6.212828,"twenty":-16.718804,"median":-9.508222,"eighty":-8.310046,"marketCap":19460065572},{"date":"2026-07-10","current":-6.457487,"twenty":-16.608112,"median":-9.462457,"eighty":-8.218812,"marketCap":20201573647},{"date":"2026-07-17","current":-6.192643,"twenty":-16.533051,"median":-9.445101,"eighty":-8.097368,"marketCap":19441980010},{"date":"2026-07-24","current":-6.744145,"twenty":-16.505793,"median":-9.428231,"eighty":-7.995787,"marketCap":21178194038},{"date":"2026-07-31","current":-5.225281,"twenty":-16.472851,"median":-9.409879,"eighty":-7.856069,"marketCap":16439776585},{"date":"2026-08-07","current":-5.555188,"twenty":-16.434203,"median":-9.398864,"eighty":-7.73561,"marketCap":17511664790},{"date":"2026-08-14","current":-5.519506,"twenty":-16.417169,"median":-9.342917,"eighty":-7.473767,"marketCap":17421211976},{"date":"2026-08-21","current":-5.561665,"twenty":-16.354018,"median":-9.310353,"eighty":-6.918832,"marketCap":17593072323},{"date":"2026-08-28","current":-5.723357,"twenty":-16.253166,"median":-9.270261,"eighty":-6.767757,"marketCap":18108653362}],"updateTime":1787993629179},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1106943166","title":"异动解读｜映恩生物-B盘中上涨5.56%，瑞银首次覆盖给予买入评级叠加板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1106943166","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106943166?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 09:44","pubTimestamp":1787190241,"startTime":"0","endTime":"0","summary":"8月20日，映恩生物-B盘中上涨5.56%，报194.5港元/股，成交额3997.93万港元。消息面上，瑞银近日首次覆盖映恩生物-B，给予\"买入\"评级，目标价320港元，较当前股价存在约65%的上行空间。瑞银指出公司现价仅对应0.7倍风险调整后峰值销售比率，远低于同业中位数的1.6倍，估值吸引。此外，招商证券、东吴证券、中国银河证券近期亦先后首次覆盖并给予积极评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.56%，瑞银首次覆盖给予买入评级叠加板块走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101371","title":"瑞银：映恩生物-B首次覆盖给予“买入”评级 目标价320港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101371","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101371?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 11:02","pubTimestamp":1786935720,"startTime":"0","endTime":"0","summary":"模拟交易客户端瑞银发布研报称，首次覆盖映恩生物-B，给予“买入”评级，基于风险调整后现金流折现估值，目标价320港元，对应1.2倍风险调整后峰值销售比率。映恩生物是一家专注于新型抗体药物偶联物研发的临床阶段生物科技公司。该行预计DB-1311将成为主要估值驱动力，预测其峰值销售达383亿元人民币，高于市场共识的286亿元人民币。该行预测2025年总收入（未调整）将由18亿元人民币升至2035年的228亿元人民币，EBITDA预计在2030年转正。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-17/doc-ininqtns0338953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193925469","title":"异动解读｜映恩生物-B盘中下跌5.14%，报182.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193925469","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193925469?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 09:51","pubTimestamp":1786931510,"startTime":"0","endTime":"0","summary":"8月17日，映恩生物-B盘中下跌5.14%，报182.7港元/股，成交额2591.9万港元。映恩生物-B所在的生物科技行业中，个股表现分化，康方生物跌6.67%，信达生物涨0.96%，百济神州涨0.85%，荣昌生物跌2.23%，三生制药跌3.42%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303、DB-1311、DB-1310、DB-1305等，覆盖乳腺癌、子宫内膜癌、肺癌等多个适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660061091","title":"瑞银：首次复盖映恩生物-B(09606.HK)予“买入”评级 目标价320港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660061091","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660061091?lang=zh_cn&edition=fundamental","pubTime":"2026-08-17 09:15","pubTimestamp":1786929349,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000500386.USD","09606","LU2543165471.USD","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659814819","title":"《大行》瑞银首次覆盖映恩生物(09606.HK)予“买入”评级  目标价320元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659814819","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659814819?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 18:07","pubTimestamp":1786702020,"startTime":"0","endTime":"0","summary":"瑞银发表研究报告，首次覆盖映恩生物-B，给予“买入”评级，基于风险调整后现金流折现估值，目标价320港元，对应1.2倍风险调整后峰值销售比率。映恩生物是一家专注于新型抗体药物偶联物研发的临床阶段生物科技公司。多个候选药物在研发进度上位居全球前三，并已与BioNTech、GSK、百济神州及Avenzo等全球制药公司建立合作，交易总值超过60亿美元。该行预测2025年总收入(未调整)将由18亿元人民币升至2035年的228亿元人民币，EBITDA预计在2030年转正。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250409114926459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250409114926459_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538426/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538426/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157327363","title":"映恩生物-B(09606)拟于2026年8月28日审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1157327363","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157327363?lang=zh_cn&edition=fundamental","pubTime":"2026-08-14 16:36","pubTimestamp":1786696594,"startTime":"0","endTime":"0","summary":"映恩生物-B（09606）8月14日公告，公司董事会将于2026年8月28日（星期五）召开会议，审议并批准截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。届时，董事会亦将处理其他相关事项。\n截至本公告日期，映恩生物-B董事会成员包括：  \n1. 执行董事：朱忠远博士（董事会主席兼首席执行官）、张韶壬先生、花海清博士；  \n2. 非执行董事：蔡志洋先生、余涛博士；  \n3. 独立非执行董事：谢东先生、高凤勇先生、揣姝茵女士。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658921431","title":"【券商聚焦】招商证券首予映恩生物（09606）强烈推荐评级 指ADC管线差异化优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2658921431","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658921431?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 14:39","pubTimestamp":1786516786,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招商证券发布研报指，映恩生物 凭借四大自主知识产权ADC技术平台，构建了覆盖肿瘤与自免疾病、从1.0到3.0全梯度的差异化管线。DB-1303针对二线及以上HER2阳性乳腺癌的III期研究已达PFS主要终点，中国BLA于2026年4月获NMPA受理；其子宫内膜癌适应症获中美突破性疗法认定，为全球少数覆盖全HER2表达水平的HER2 ADC。首次覆盖，给予“强烈推荐”投资评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","KCE","09606","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106331638","title":"异动解读｜映恩生物-B盘中上涨5.28%，生物科技板块集体走强延续估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1106331638","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106331638?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 11:52","pubTimestamp":1786420323,"startTime":"0","endTime":"0","summary":"8月11日，映恩生物-B盘中上涨5.28%，报205.4港元，成交额1.03亿港元。该股此前因GSK竞争压力于7月30日大跌后持续修复，本次上涨主要受生物科技板块集体走强带动。消息面上，同行业个股今日普涨，百济神州涨4.41%、再鼎医药涨4.6%、康方生物涨2.76%，板块情绪延续回暖。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172376984","title":"异动解读｜映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1172376984","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172376984?lang=zh_cn&edition=fundamental","pubTime":"2026-08-07 14:17","pubTimestamp":1786083478,"startTime":"0","endTime":"0","summary":"8月7日，映恩生物-B盘中上涨5.09%，报191.9港元，成交额1.48亿港元。该股此前因GSK竞争压力于7月30日大跌13.7%，近期逐步企稳修复。消息面上，港股生物科技板块今日整体走强，荣昌生物涨9.12%、药捷安康-B涨6.94%、百济神州涨5.16%、康方生物涨4.06%，板块情绪显著回暖带动映恩生物跟涨。此外，公司核心管线B7-H3 ADC此前获NMPA突破性疗法认定，科创板IPO申请已获上交所受理并进入已问询阶段，多家券商给予\"买入\"评级，基本面利好持续积累支撑估值修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160159290","title":"映恩生物-B更新2026年7月股份变动月报表，总股本增至91,224,314股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160159290","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160159290?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 16:49","pubTimestamp":1785919773,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年8月5日披露2026年7月股份变动月报表。报告显示，截至本月末，公司法定注册股本维持在200,000,000股普通股不变，每股面值0.0001美元，法定注册股本总额保持在20,000美元。公司表示，其已符合香港联交所主板上市规则相关的公众持股量最低要求。公司亦确认，其在本月的所有股份发行或库存股出售与转让事宜均严格遵照香港联交所《上市规则》和相关法律法规的规定执行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123746970","title":"异动解读｜映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1123746970","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123746970?lang=zh_cn&edition=fundamental","pubTime":"2026-08-04 13:23","pubTimestamp":1785820995,"startTime":"0","endTime":"0","summary":"8月4日，映恩生物-B盘中上涨5.15%，报189.8港元，成交额1.3亿港元。此前该股因GSK竞争压力连续调整，7月30日大跌13.7%，8月3日再跌5.23%，当前出现明显反弹。消息面上，药明康德半年报业绩超预期并全面上调全年指引，显著提振创新药产业链信心，港股通创新药ETF整体走强，映恩生物-B受板块情绪带动。此外，公司核心管线B7-H3 ADC Elfe-D近期获NMPA突破性疗法认定，海内外均获监管认可，多家券商给予\"买入\"评级，基本面支撑逐步修复市场信心。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174620861","title":"异动解读｜映恩生物-B盘中下跌5.23%，GSK竞争压力与减持忧虑延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1174620861","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174620861?lang=zh_cn&edition=fundamental","pubTime":"2026-08-03 09:45","pubTimestamp":1785721512,"startTime":"0","endTime":"0","summary":"8月3日，映恩生物-B盘中下跌5.23%，报172.6港元，成交额2716.64万港元。消息面上，此前葛兰素史克（GSK）在半年报中大幅提升其B7-H3 ADC管线Ris-Rez的战略优先级，将其定义为2031年后肿瘤业务增长核心，直接冲击映恩生物核心管线DB-1311的竞争格局。该股7月30日已大跌13.7%，当前延续调整态势。此外，市场对基石投资者解禁后的减持压力亦存担忧，叠加公司行权Co-Co模式后需持续投入大量研发资金，资金链压力受到关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181533841","title":"一周港股牛熊榜 | 海致科技周涨40%问鼎牛榜榜首；清盘人重启股权出售计划，恒大物业周涨23%；伟禄科技暴跌33%，遭大股东减持12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181533841","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181533841?lang=zh_cn&edition=fundamental","pubTime":"2026-07-31 19:35","pubTimestamp":1785497713,"startTime":"0","endTime":"0","summary":"7月全月恒指累升3,003点或13.1%。该股7月21日盘中一度跌33%至111港元，此前7月17日尚报203.60港元。张先生通过其或透过其控制的实体计划于未来6个月增持价值介乎3.0亿港元至6.0亿港元的股份。下一步，计划邀请潜在买方对集团进行尽职调查。出售事项后，美林控股持有7.33亿股股份，占本公司已发行股本总额约50.83%。美林控股进一步告知董事会，据其深知、尽悉及确信，于出售事项前，买方为本公司及其关连人士的独立第三方","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09903","02706","01888","06666","01783","06887","02687","09606","06166","01196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654092391","title":"映恩生物－Ｂ(09606)股价下跌5.038%，现价港币$222.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2654092391","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654092391?lang=zh_cn&edition=fundamental","pubTime":"2026-07-27 14:04","pubTimestamp":1785132240,"startTime":"0","endTime":"0","summary":"[下跌股]映恩生物－Ｂ(09606) 股价在下午02:03比前收市价下跌5.038%，现股价为港币$222.4。至目前为止，今日最高价为$237.0，而最低价为$222.4。总成交量为29.95万股，总成交金额为港币$6.852千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607272189/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607272189/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2543165471.USD","BK1161","HK0000252160.HKD","09606","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653221532","title":"【券商聚焦】中国银河证券首予映恩生物(09606)推荐评级 指其ADC管线梯队完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2653221532","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653221532?lang=zh_cn&edition=fundamental","pubTime":"2026-07-21 15:31","pubTimestamp":1784619085,"startTime":"0","endTime":"0","summary":"DB-1303安全性可控，HER2阳性乳腺癌已递交上市申请，填补HER2低表达患者治疗空白。DB-1310针对EGFR靶向耐药肺癌，多线人群ORR达43.5%。DB-1305联合双抗一线三阴性乳腺癌确认超高缓解率。创新管线中，全球首创自免ADC DB-2304靶向BDCA2，直击红斑狼疮未满足临床需求，已推进至IIa期。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","161027","601881","09606","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111245137","title":"异动解读｜映恩生物-B盘中下跌5.15%，报228.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111245137","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111245137?lang=zh_cn&edition=fundamental","pubTime":"2026-07-21 10:15","pubTimestamp":1784600144,"startTime":"0","endTime":"0","summary":"7月21日，映恩生物-B盘中下跌5.15%，报228.4港元/股，成交额5300.47万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，百济神州跌2.19%，康方生物跌3.05%，信达生物跌2.49%，科伦博泰生物跌0.99%，三生制药跌2.24%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310等，公司主要在国内和国外市场开展业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652337216","title":"智通港股解盘 | 魔咒解除各种刺激再起 Token概念股走势凶猛","url":"https://stock-news.laohu8.com/highlight/detail?id=2652337216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652337216?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 21:00","pubTimestamp":1784552412,"startTime":"0","endTime":"0","summary":"7月20日，中煤能源、中国神华发布分红增持利好。其中，中煤能源公告称，控股股东拟5000万元至1亿元增持公司股份。港股中国软件国际今日正式宣布与月之暗面正式签署“登月计划”之Token分成及联合创新合作协议。公司预计上半年收入同比增长13%至14%，归属股东净利润约4000万至6000万元，实现扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1163","BK1613","LU0456827905.SGD","BK1161","BK1607","HK0000500386.USD","LU1813983027.USD","BK1109","LU0051755006.USD","BK1526","LU2039709279.SGD","HK0000252152.HKD","BK1155","BK1586","LU0052750758.USD","VXUS","09606","BK1530","00268","LU0708995583.HKD","BK4585","01898","LU1023057109.AUD","LU0320764599.SGD","00991","BK1125","BK1178","LU0314109678.HKD","BK4588","LU0359201612.USD","BK1538","LU2543165471.USD","IE0034224299.USD","LU0359201885.HKD","KCAI","LU0359202008.SGD","HK0000252160.HKD","BK1594","LU1328277881.USD","LU0072462343.USD","03986","03317","BK1518","LU1048588211.SGD","BK1517","BK1618"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2652262259","title":"港股异动 | 映恩生物-B(09606.HK)午后涨近15% B7-H3 ADC拟纳入突破性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2652262259","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652262259?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 13:38","pubTimestamp":1784525921,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","HK0000252152.HKD","LU2543165471.USD","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196132904","title":"异动解读｜映恩生物-B盘中上涨7.07%，DB-1310临床数据披露叠加合作方Avenzo完成纳斯达克上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1196132904","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196132904?lang=zh_cn&edition=fundamental","pubTime":"2026-07-20 10:32","pubTimestamp":1784514722,"startTime":"0","endTime":"0","summary":"7月20日，映恩生物-B盘中上涨7.07%，报230.2港元/股，成交额1.19亿港元。消息面上，公司近日在ASCO大会上以口头报告形式首次公布DB-1310用于治疗晚期实体瘤患者的I/IIa期试验初步结果，该品种此前已与阿斯利康就联合奥希替尼的临床探索达成合作。同时，合作方Avenzo于7月16日宣布通过反向合并实现纳斯达克上市，并完成2.15亿美元超额认购PIPE融资，其核心资产之一即为从映恩生物引进的EGFR/HER3双抗ADC DB-1418，进一步验证公司管线商业价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119752477","title":"异动解读｜映恩生物-B盘中下跌5.99%，报220.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119752477","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119752477?lang=zh_cn&edition=fundamental","pubTime":"2026-07-17 10:01","pubTimestamp":1784253660,"startTime":"0","endTime":"0","summary":"7月17日，映恩生物-B盘中下跌5.99%，报220.8港元/股，成交额5256.0万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，康方生物跌7.71%，三生制药跌6.98%，科伦博泰生物跌4.65%，信达生物跌2.49%，百济神州跌2.15%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，公司主要在国内和国外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":144,"code":"91000000","status":"200"}]}}